EW stock: buy or sell?

EW stock price: $222.50 1.44% At close on August 19th, 2019

Updated on:
August 19th, 2019


Edwards Lifesciences shares peaked new all time highs again today, setting highs to $223.95. Shares ended at $222.50 and inched 1.44%. Counting Monday, it's been 3 green days in a row, gaining $8.99 or 4.10%.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally.

Should I buy EW stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

These 2 buy setups work for Edwards Lifesciences stock right now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Edwards Lifesciences stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 15 ratings published for EW stock in the last month.

The general sentiment of these ratings is bullish for EW stock, with 12 positive ratings.
Is EW a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-7-25BTIG Researchn/aHold
2019-7-24Wells Fargo & Con/aOutperform
2019-7-24Raymond Jamesn/aOutperform
2019-7-24Raymond Jamesn/aOutperform
2019-7-24Morgan Stanleyn/aOverweight
2019-7-24JPMorgan Chase & Co.n/aNeutral
2019-7-24Jefferies Financial Groupn/aBuy
2019-7-24Credit Suisse Groupn/aOutperform
2019-7-24Canaccord Genuityn/aBuy
2019-7-24BMO Capital Marketsn/aOutperform
2019-7-24Bank of AmericaBuyBuy
2019-7-16Morgan Stanleyn/aOverweight
2019-4-24Raymond JamesOutperformOutperform
2019-4-24Jefferies Financial Groupn/aBuy

EW stock analysis

Daily outlook

Edwards Lifesciences inched 1.44% today and peaked a new all time high at $223.95.

Edwards Lifesciences shares inched 1.44% today and peaked a new all time high at $223.95. EW shows a sign of strength in the short-term after finally breaking out above $219.70 on Tuesday and marking a new rising bottom. Since last Jul 11th when SMA50d and SMA100d crossed up, EW price gained $31.32 per share (16.38%). Since last June when EW stock price broke up the SMA100d line, it gained $48.46 (27.84%).

EW stock chart (daily)

Weekly outlook

Edwards Lifesciences topped new all time highs again this week, marking to $223.95. Shares ended at $222.50 and raised 1.44% during the week. With this, it's been 5 climbing weeks in a row, soaring a 14.71%. Late July EW boosted an astounding 8.70% in just one week.

Edwards Lifesciences stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, EW might consolidate in a flat-base, waiting to break out over or down under . Late December 2018 EW price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

EW stock chart (weekly)

EW stock price history

EW IPO was on March 27th, 2000 at $3.81 per share1. Since then, EW stock grew a 5,739.90%, with an average of 302.10% per year. If you had invested right after EW's IPO a $1,000 in EW stock in 2000, it would worth $57,399.00 today.

1: Adjusted price after possible price splits or reverse-splits.

EW stock historical price chart

EW stock reached all-time highs today with a price of $223.95.

EW stock price target is $221.60

Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' EW stock price predictions in the hope that they will be met as they may be wrong and not met. We found 14 price targets for Edwards Lifesciences stock published in the last 30 days:
EW stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-24Wells Fargo & CoReiterates$207.00$220.006.3%
2019-7-24Raymond JamesReiterates$200.00$232.0016%
2019-7-24Raymond JamesRaises Target$200.00$232.0016%
2019-7-24Morgan StanleyRaises Target$210.00$228.008.6%
2019-7-24JPMorgan Chase & Co.Raises Target$190.00$225.0018.4%
2019-7-24Jefferies Financial GroupReiterates$210.00$245.0016.7%
2019-7-24Credit Suisse GroupReiterates$221.00$226.002.3%
2019-7-24Canaccord GenuityReiterates$215.00$250.0016.3%
2019-7-24BMO Capital MarketsReiterates$204.00$224.009.8%
2019-7-24BarclaysRaises Target$160.00$175.009.4%
2019-7-24Bank of AmericaReiterates$215.00$225.004.7%
2019-7-16Morgan StanleyRaises Target$197.00$210.006.6%
2019-4-24Raymond JamesLowers Target$210.00$200.00-4.8%
2019-4-24Jefferies Financial GroupRaises Target$195.00$210.007.7%
(in average)$202.40$221.609.0%
The price target for Edwards Lifesciences stock is $221.60, moving in a range between $250.00 and $175.00. In average, analysts' outlook on EW price target is positive, upgrading the prediction by a 9.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report on April, Edwards Lifesciences rocketed an astounding 24.81%. Unfortunately, reported EPS is not yet available in our database.
EW earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual revenues report draw an excellent increase of 8.37% to $3,722.80 million dollars. Instead, its profit margin (compared to revenues) gained to 19.40%, that is $722.20 million.

To have an up to date view of the financial situation of Edwards Lifesciences, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Edwards Lifesciences TTM sales up to March 2019 were $3,821.00 and earnings were $765.30 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Edwards Lifesciences business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, raised a slightly good 2.64%. Regarding profit margin, Edwards Lifesciences remained steady 0.63% to 19.40%

EW annual Sales and Income evolution
2013$2,050 M-$392 M19.1%-
2014$2,323 M13.31%$811 M34.9%107.07%
2015$2,494 M7.35%$495 M19.8%-38.98%
2016$2,964 M18.85%$570 M19.2%15.07%
2017$3,435 M15.91%$584 M17.0%2.48%
2018$3,723 M8.37%$722 M19.4%23.75%
TTM $3,821 M2.64%$765 M20.0%5.97%

Quarterly financial results

Edwards Lifesciences reported $993.00 M in revenues for 2019-Q1, a 1.56% up compared to previous quarter. Reported quarter income marked $249.70 M with a profit margin of 25.15%. Profit margin skyrocketed a 24.43% compared to previous quarter when profit margin was 0.72%. When comparing turnover to same quarter last year, Edwards Lifesciences sales marked a superb increase and boosted a 10.97%. Looking back to recent quarterly results, Edwards Lifesciences posted 2 negative quarters in a row.
EW quarterly Sales and Income evolution
2017-Q2$842 M-$186 M22.1%-
2017-Q3$822 M-2.41%$170 M20.7%-8.60%
2017-Q4$889 M8.16%$-3 M-0.3%-101.65%
2018-Q1$895 M0.71%$207 M23.1%-7,478.57%
2018-Q2$944 M5.46%$283 M30.0%36.83%
2018-Q3$907 M-3.93%$226 M24.9%-20.09%
2018-Q4$978 M7.84%$7 M0.7%-96.90%
2019-Q1$993 M1.56%$250 M25.1%3,467.14%

Edwards Lifesciences ownership

When you are planning to invest in shares of a company, it's worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Edwards Lifesciences, 3.94% of all outstanding shares are owned by its staff.

In case of Edwards Lifesciences stock, 0.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for EW stock account 0.00%, no big difference from last month.

For a better context understanding, the next table shows ownership data compared to other related companies:

Market cap$46.3 B$59.4 B$985.4 M$3.4 B$620.0 M
Total shares208.1 M1,390.0 M37.3 M20.6 M19.7 M
Float shares206.6 M1,390.0 M35.9 M19.2 M15.9 M
  - Institutional holdings (%)0.0%93.4%72.1%93.5%77.8%
  - Insider holdings (%)3.9%0.2%3.8%7.1%18.5%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

EW summary

Monday, August 19th, 2019
Day range$220.24 - $223.95
Previous close$219.34
Session gain1.44%
Average true range$5.11
50d mov avg$199.05
100d mov avg$189.45
200d mov avg$176.63
Daily patternlb02c
Weekly pattern lt06a

Edwards Lifesciences performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We chose Boston Scientific, CryoLife, ICU Medical, LeMaitre Vascular, Medtronic and Merit Medical Systems as the bechmarking frame for Edwards Lifesciences stock.
EWEdwards Lifescien...31.36%28.98%56.99%
BSXBoston Scientific11.07%5.45%23.07%
ICUIICU Medical-26.09%-34.46%-43.62%
LMATLeMaitre Vascular14.95%26.08%-14.14%
MMSIMerit Medical Sys...-34.09%-39.30%-36.13%

Edwards Lifesciences competitors

We picked a few stocks to conform a list of Edwards Lifesciences competitors to check if you are interested in investing in EW:

Latest EW stock news